Eloxatin is a brand name of oxaliplatin, approved by the FDA in the following formulation(s):
ELOXATIN (oxaliplatin - injectable; iv (infusion))
Manufacturer: SANOFI AVENTIS US
Approval date: January 31, 2005
Strength(s): 100MG/20ML (5MG/ML) [RLD][AP], 50MG/10ML (5MG/ML) [RLD][AP]
Manufacturer: SANOFI AVENTIS US
Approval date: November 17, 2006
Strength(s): 200MG/40ML (5MG/ML) [RLD]
Has a generic version of Eloxatin been approved?
A generic version of Eloxatin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Eloxatin and have been approved by the FDA:
oxaliplatin injectable; iv (infusion)
Manufacturer: EBEWE PHARMA
Approval date: August 7, 2009
Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]
Manufacturer: FRESENIUS KABI ONCOL
Approval date: June 10, 2010
Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]
Manufacturer: HOSPIRA WORLDWIDE
Approval date: August 7, 2009
Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]
Manufacturer: SANDOZ
Approval date: January 24, 2011
Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]
Manufacturer: TEVA PARENTERAL
Approval date: August 7, 2009
Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eloxatin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Platinum compound and process of preparing same
Patent 5,290,961
Issued: March 1, 1994
Inventor(s): Okamoto; Koji & Hoshi; Yuko & Nakanishi; Chihiro
Assignee(s): Tanaka Kikinzoku Kogyo K.K.
Disclosed herein are a platinum compound employed as raw material of medicines having carcinostatic effects, and a process of preparing the platinum compound. The platinum compound (I) substantially free from impurities can be prepared through a reaction between the corresponding dihalogen compound and an organic dibasic acid employing an iodine compound utilizing the difference of solubilities between the desired compound and the iodine compounds.Patent expiration dates:
- January 12, 2013✓
- July 12, 2013✓
- January 12, 2013
Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity
Patent 5,338,874
Issued: August 16, 1994
Inventor(s): Nakanishi; Chihiro & Ohnishi; Yuko & Ohnishi; Junji & Taniuchi; Junichi & Okamoto; Koji & Tozawa; Takeshi
Assignee(s): Tanaka Kikinzoku Kogyo K.K.
Disclosed herein is cis-oxalato (trans-1-1,2-cyclohexanediamine) Pt(II) optically high purity. Because of its complete optical purity, the compound is effective as raw material of such a medicine as a carcinostatic agent. The complete optical purity of the above compound may be proved by comparing the respective melting points of the cis-oxalato (trans-1-1,2-cyclohexanediamine).Patent expiration dates:
- April 7, 2013✓
- October 7, 2013✓
- April 7, 2013
Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same
Patent 5,420,319
Issued: May 30, 1995
Inventor(s): Okamoto; Koji & Nakanishi; Chihiro & Taniuchi; Junichi & Ohnishi; Junji & Komoda; Yasunobu
Assignee(s): Tanaka Kikinzoku Kogyo K.K.
Disclosed is cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and no toxicity and exhibiting anticancer performance, as shown in the below Formula. Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex of the invention possesses high optical purity or 99.94% or more e.e. and a melting point of 198.3.degree. to 199.7.degree. C. The complex is synthesized employing as starting material trans-1-1,2-cyclohexamediamine or a derivative of the trans-1-1,2-cyclohexanediamine optically resoluted by means of a high performance liquid chromatography. ##STR1##Patent expiration dates:
- August 9, 2016✓
- February 9, 2017✓
- August 9, 2016
Pharmaceutically stable preparation of oxaliplatinum
Patent 5,716,988
Issued: February 10, 1998
Inventor(s): Ibrahim; Houssam & Mauvernay; Rolland-Yves
Assignee(s): Debiopharm S.A.
A pharmaceutically stable oxaliplatinum preparation for parenteral administration comprises an aqueous solution of oxaliplatinum, in a concentration of 1 to 5 mg/ml, and with a pH in the range of 4.5 to 6. The aqueous oxaliplatinum solution is advantageously provided as a ready-to-use preparation in a sealed container.Patent expiration dates:
- August 7, 2015✓
- February 7, 2016✓
- August 7, 2015
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- July 10, 2010 - PEDIATRIC EXCLUSIVITY
See also...
- Eloxatin Consumer Information (Drugs.com)
- Eloxatin Consumer Information (Wolters Kluwer)
- Eloxatin Consumer Information (Cerner Multum)
- Eloxatin Advanced Consumer Information (Micromedex)
- Eloxatin AHFS DI Monographs (ASHP)
- Oxaliplatin Consumer Information (Wolters Kluwer)
- Oxaliplatin Consumer Information (Cerner Multum)
- Oxaliplatin Intravenous Advanced Consumer Information (Micromedex)
- Oxaliplatin AHFS DI Monographs (ASHP)
No comments:
Post a Comment